IN8bio, Inc.(INAB)

$1.44—

Chart

IN8bio, Inc.(INAB)

NASDAQ

$1.44—

Chart Studio

INAB(INAB)

INAB

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

7/16/26

IN8BIO (INAB)

Thursday

12:18 AM

Thesis: Recent market trends and increased competition in the oncology space have led to a more cautious outlook among investors regarding IN8bio's growth potential.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$0.00	$48M	$1M
Rev. Growth	—	—	-97.7%
EPS	$-4.44	$-1.24	$-1.06
EPS Growth	-679%	+72.0%	+14.6%
P/E	—	—	—

★ Analysts see FY2027 revenue reaching $1M — -97.7% growth in a single year.

What Could Go Wrong

1Increased competition from emerging therapies in glioblastoma treatment could pressure market share and pricing power.
2Potential delays in clinical trial timelines due to regulatory hurdles could negatively impact investor sentiment.
3Regulatory changes that could impact approval processes for new therapies
4Technological disruption in cancer treatment methodologies
5Emergence of new therapies targeting the same cancer indications
6Potential partnerships between larger competitors and other biotech firms
7High cash burn rate due to ongoing clinical trials and R&D expenses
8Limited revenue generation could strain liquidity if funding is not secured

FY2025 Snapshot

Revenue: $0.00
Gross Margin: 0.0%
Op. Margin: 0.0%
Net Margin: 0.0%
Net Income: $-19M
NI Growth: +36.1%
EPS: $-4.44
1Y Return: -35.1%

INAB Chart

My Notes

"The landscape for cancer therapies is rapidly evolving, and we must remain vigilant in our strategic positioning."
Moat: IN8bio's proprietary technology and focus on difficult-to-treat tumors provide a moderate level of competitive advantage.
Watch: The rapid advancement of CAR-T and other immunotherapies poses a significant threat to IN8bio's market position.
growth - Investors seeking high-risk, high-reward opportunities in the biotechnology sector.
Moderate - Rising interest rates could increase the cost of capital for IN8bio, impacting its ability to fund R&D and clinical trials…
Watch on earnings: Clinical trial enrollment rates for IN8-001, Cash runway based on current burn rate, Partnership announcements and their financial implications.

One Sentence Summary:

The bear case: increased competition from emerging therapies in glioblastoma treatment could pressure market share and pricing power.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

FY2027E

—

P/E

—

What Could Go Wrong

1Increased competition from emerging therapies in glioblastoma treatment could pressure market share and pricing power.

2Potential delays in clinical trial timelines due to regulatory hurdles could negatively impact investor sentiment.

3Regulatory changes that could impact approval processes for new therapies

4Technological disruption in cancer treatment methodologies

5Emergence of new therapies targeting the same cancer indications

6Potential partnerships between larger competitors and other biotech firms

7High cash burn rate due to ongoing clinical trials and R&D expenses

8Limited revenue generation could strain liquidity if funding is not secured

My Notes

"The landscape for cancer therapies is rapidly evolving, and we must remain vigilant in our strategic positioning."

Moat: IN8bio's proprietary technology and focus on difficult-to-treat tumors provide a moderate level of competitive advantage.

Watch: The rapid advancement of CAR-T and other immunotherapies poses a significant threat to IN8bio's market position.

growth - Investors seeking high-risk, high-reward opportunities in the biotechnology sector.

Moderate - Rising interest rates could increase the cost of capital for IN8bio, impacting its ability to fund R&D and clinical trials…

Watch on earnings: Clinical trial enrollment rates for IN8-001, Cash runway based on current burn rate, Partnership announcements and their financial implications.